PulseSight Therapeutics SAS to present data on PST-611 for dry AMD/GA
The European Association for Vision and Eye Research 27th EVER Congress will be held in Valencia, Spain, November 3 – 5, 2024.
(Image credit: AdobeStock/Right 3)
PulseSight Therapeutics SAS will be presenting data on its lead program PST-611, expressing human transferrin, in dry age-related macular degeneration (AMD)/geographic atrophy (GA) at the European Association for Vision and Eye Research 27th EVER Congress, being held in Valencia, Spain, November 3 – 5, 2024.
The company has an oral and a poster presentation accepted. These are:
- Oral Presentation by Dr Thierry Bordet (CSO): Transferrin is a drug candidate for the treatment of geographic atrophy (GA)/dry age-related macular degeneration (AMD)
Presentation on November 5, 2024, 9:20 am -10:35 am CET - Poster Presentation by Dr Karine Bigot (Head Pharmacology & Toxicology): Non-clinical safety of PST-611, non-viral vectorized human transferrin, for the treatment of geographic atrophy (GA)
Presentation on November 5, 2024, 11:05 am -12:05 pm CET
Thierry Bordet, CSO of PulseSight Therapeutics, said spoke about this meeting in the press release1, saying, “EVER attracts top European researchers and the most innovative industry players, and I am delighted that we have been accepted to present our recent promising data on PST-611, our pioneering, first-in-class non-viral vectorized gene therapy for the treatment of dry AMD/GA. PST-611 is a DNA plasmid encoding human transferrin, a highly potent iron chelator. Excess iron is known to be highly toxic to retinal cells, leading to oxidative stress, inflammation, and ferroptosis. By restoring normal iron homeostasis, transferrin mitigates these toxic effects and protects retinal cells, offering the potential to slow GA lesions growth and improve patient’s visual function. Additionally, PST-611 benefits from a very good safety profile, as will be presented by my colleague Karine, further supported by the safety data from an earlier clinical trial with our previous candidate (PST-606 in uveitis).”
In addition to announcing these upcoming presentations, the company also shared in their press release that it plans to submit a phase I clinical trial authorization (CTA) by end of October 2024. The intent is for this to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its drug candidate by the end of 2027.1
